good joining Thanks us progress for afternoon for and everyone. Thanks recent Chris, CytomX. an update at on
our of our to like would a start a I to Medical Chief new welcome pipeline, Officer, moment taking moving to review Wayne Before by Chu.
candidates. of Wayne clinical therapeutic of which he the capacity are body on development as in Officer, portfolio diversified will thrilled board We to Chief have Medical our oversee pro
and lead drug drug multiple therapeutic clinical including the as immunotherapies, modalities, and Pipeline. and work optimize date drug him and CytomX our fit development him been extensive experience Wayne’s inhibitors, checkpoint spans to know to milestones. am his closely with ideal is towards to we team key excited career an approvals execute conjugates, I of Wayne, making get bispecific the strategy pleasure It has to contributed a to new and over to antibody development
like I of promotion Dawn of than Product to experience her industry. and on in as contributor head Manufacturing brings moving Senior would President Benson Quality her this Additionally, a execution, to in CMC more expanded Vice congratulate and announced XXXX quality today. have quality joined XX-years has to of Dawn and newly and been CytomX biotech strong are Dawn the role. CytomX delighted key we recent into to
and exciting highly During and disciplined company time across This is QX, our us. execution maintained an for areas CytomX pipeline. focused of all
active We more wholly-owned are XX prosecuting than and partnered programs across our pipeline.
We are financed. well
have points goals as we and ahead Our to been and inflection potential approaching are XXXX multiple beyond. look we clearer, never
this perspective for evolution cover current CytomX generation moment our make and to and I the the difference course’s our pipeline, share patients. potential like take platform progress, on provide of to programs a a I Before some to to would meaningful optimism of how the have
an unwavering formats continues conjugates, maintained increasingly and cytokines. conditionally commitment oncology we CytomX, to active the drug localized As At advancing such improve immunotherapies of bispecific biologics therapeutic potent as evolve field R&D to to towards window. have antibody
and that therapeutic discovery oncology activation for to development. strategy therapies increasingly of conditional field believe novel future is will a is and The the as We biologics. grow localized continuing established mature, and be becoming
We are including judicious and to CX-XXX, believe programs, driven by CytomX choices generation bench making for XX-years current of tumor leadership more clinical well this bedside of selection, our The our molecules and unmatched depth field, our pipeline than experience has and design informed CX-XXX CX-XXXX learnings, regarding function, experience target modality, decisions in next and effective positioned. breadth types.
the also with industry. forward Moreover, reinforce in that view Regeneron activated Moderna collaborations conditionally broadly new strategic is importance and and the partners support of and momentum with biologics localized leadership longstanding our continued our our scientific
like moving have malignancies, our development demonstrated activity benefit research significant for patients impressive our and certain solid T-cell clinical holds with in promise and antibodies I the with T-cell current would to engaging this start treatment pipeline, hematologic enormous bispecific of for bispecific’s. Now tumors. modality engaging to the area of
imposing highly therapeutic However, system syndrome T-cell lead engages in activation the cytokines window. release very form tumor potency and widespread are the modality and potent target low at off this the immune systemic to of can constraints doses, toxicities on of on of
strategies by window. pro that body localizing the for to addressing institutions date field organizations anti-cancer we challenge built of the be platform solid for the this tissue. improve class foundational by to activity in of and this highlights cytokine, base therapeutic could drugs ideally powerful At tumors into many Efforts important knowledge to need have the an tumor believe suited
with our on activation have both in body our Regeneron. Astellas, now Amgen, we modalities, program the a pro Building multiple therapeutic work past and T-cell engagers, decade over partners, conditional across and of ourselves broad
program stage area advanced CX-XXX, a pro this Our global alliance. Amgen Partnered body most co-development and in clinical EGFR targeting Engager a in T-cell with is CD-X.
more of the tissue today inhibitors many engagers. T-cell highly EGFR targets. tyrosine for target cancer have tumor EGFR that small also approved its types antibodies and targeted tumor broadly as strategies validation. interest EGFR attracted expression kinase of block various of and EGFR monoclonal one in in function given been including are validated as use has most oncogenic growth recently an several Four is tumor and for clinical clinical a the expressed bispecific driver widespread solid treatment molecule.
based published Cetuximab. seminal target. Building based is EGFR unlock the T-cell pro work body positioned blocking antibodies to Cytokine on first ideally a described EGFR the therapeutic protease as we the previously that engager on
substantially EGFR that opening maintaining explore and systemic that of an antibody on empowered a effects associated reduced activity, an to while EGFR demonstrated masking strategy work based Cetuximab window Our therapy with CD-X it tumor combines side commonly antibody targeting.
CX-XXX. research ongoing would evaluation in and published to like a QX in we for clinical Phase few a work from cancer our highlight pro of preclinical our launched validation in key evaluation of strategy this also CD-X preclinical CX-XXX that set was the Our - body EGFR XXXX, clinic. points I the of framework recently X
mentioned As T-cell potent, affinity of ranges The to format unmasked weights dose unmasked per owing although engagers can are micrograms other cross pharmacologically highly molecular challenging active T-cell be earlier, in kilogram. order of variables. engagers be and can I the generally comparisons
mask for meaningful In little the been Cytokine’s tissues, cause in those tumor therapeutic solid it perspective. binding tumors and this room potency, lead target from to in between to engagers promise. example, that reduce to to shrinkage, has a index great normal context to Leveraging doses of separation probiotic leaving has high CRS, difficult maneuver that to date T-cell therefore, show technology
tolerated and Our point XX potency XX EGFR emphasized less masked this activity. of the strong fold dose preclinical induction for anti-tumor research systemic engagers showing maintaining release higher with maximum in cytokine while fold strongly vivo, T-cell
the We our into advancing translating preclinical this clinic are research X process in Phase is program now the of and well.
We window cohorts successfully the we and this dose tumors, backfill excellent treated goal of clinical and levels into our positive therapeutic in of of our to certain into year to by towards the XXXX, continue reaching facilitate patient insights May, enrollment progress in the gaining EGFR exciting start agent. first activity this make end of
Phase first be partner working Phase for of escalation conjunction Phase cohorts. X X we XXXX. be share the dose of the will We These aim towards XB selection the initial with in CX-XXX dose recommended will initiation data decisions taken of half our Also to and in expansion XXXX, Amgen. in
generation will the CX-XXXX update for on now next to I programs and move an our CX-XXX. INDs upcoming
owned, the company’s on build programs ADC known these TROP-X. Starting mentioned, active as adhesion conditionally molecules. EpCAM, targeting first-generation our collective cell are have wholly I CX-XXXX epithelial As moleculeor experience body, with pro clinical also with
therapeutic clinically and by been for others, due compelling limited epithelial but mechanism cancers sensitivity. by has CX-XXXX oncology for of window expressing matching is target EpCAM local to EpCAM tailored been systemic as and has validated with action with been has regarded to optimize the a to payload toxicities. administration tumor target decades generally the
a X We the payload, We inhibitor paired and these of this tecan mask a program. for class. in from choice cleavability to derivative tecan designed the the have be it the optimal protease topoisomerase a is optimized as with believe captive
types, ADCs multiple CX-XXXX tumor cancer systemically and have a cancer. In studies when wide tremendous tecan activity including Trodelvy. Given the course, preclinical multiple HERX in predicted clinical xenograft demonstrated and from has conjugated colorectal strong seen validation administered we of including with therapeutic in models, along index
We expect clinic of the to IND quarter the year, submission advancement for the XXXX. program of this model anticipate fourth ADC in in we and this this
more we demonstrate initially to filing, IND for cancer this to early clinical proof-of-concept near we forward on details which will plan for on expeditiously relevance in order program. CX-XXXX, colorectal sharing development look clinical focus and As the
brief conjugate drug antibody our on from ADC on programs, moving our update CDXX program. a just Before
track on remain of we and update strategy our the year. provide evaluate by the end to continue We to an
Interferon XB, dually approved are CX-XXX lead multiple toxicity. XB our in the program cytokine demonstrated that Alpha to within now to field. has has but is efforts cancer immunotherapeutic been Alpha in that clinical activity Moving due limited types, its an systemic interferon must the
to tumor localization activity from enormous there’s activation. towards direct believe cytokines harness systemic antica powerful strategies system potential to the We of our activity immune with away tissue their and
with CytomX checkpoint activate refractory to and combine unlock effectively tremendous and resistant cancers. may enhance and immunotherapy that responses cells T-cells inhibition, antigen-presenting stimulates or offering alpha Interferon checkpoint potential
to index CX-XXX direct dual Interferon providing Preclinically activity, action. cell killing wide profile a tumor with microenvironment. compared with has enhanced in activity interferon, unmasked along preferential the therapeutic a alpha tolerability an of also mechanism demonstrated has tumor
a wide Development most has to profile CytomX become of at a the recently Drug believe range differentiated CX-XXX June. tumor Summit preclinical The based of therapy types. combination for the presented CX-XXX potential We was in
amplify quarter As we and CX-XXX of with XXXX. initiate the trials to for CX-XXXX, clinical in XXXX fourth on in IND
BMSBMS causal combination to with Now, monotherapy two tumors. and nivo non body the solid anti study and area in work enroll BMS-XXXXXX related continues the partnership evaluating as continuing in to the few our immunotherapy with one CTLA-X phase turning in pro with our
later opened earlier XXX study in new line evaluating arm year, or a Additionally, colorectal BMS this cancer. third
our We leading investment expertise in platform RTCTLA into experience continue by given therapies. body to clinical be extensive with pro their XX encouraged four as BMS
discovery several with We are early also working programs. BMSs busy on stage
like our to ongoing partnerships. would I briefly Finally, discuss
non-diluted component our of of a business to leveraged company. bring As extend the important we the broaden reach partnerships model, into capital have strategic science, pipeline, our and core our
value that important particularly the by inherent and scope These challenging CytomX being partnerships our engages accrues from to strategy bispecific highlight platform. our in the financial The immunotherapies. latter The illustrated continued is work the innovation CytomX of today’s T-cell partnering in environment. in
the CX-XXX and Amgen, to us transformative Astellas our modality position important uniquely in this broad and to addition focus a efforts and ongoing with In play collaborations also role Regeneron work field. this our on
therapeutic oncology to based with Moderna includes new That conducting work are are focus explore also outside of mRNA Overtime, our the frontiers, also allowing and we biologics. partnerships area. us exciting the including localized some
progress into anticipate forward make look research not translation activities, from multiple programs this and time of significant flow to that to We our and is continuing currently over to factored we our across work milestone potentially clinic guidance. financial partnered the
With call that, to for provide the of the let quarter. over to financials me our Chris turn details
